Back to Browse Journals » Vascular Health and Risk Management » Volume 7

Pre-eclampsia: pathophysiology, diagnosis, and management

Authors Uzan J, Carbonnel M, Piconne O, Asmar R, Ayoubi J-M

Published Date July 2011 Volume 2011:7 Pages 467—474

DOI http://dx.doi.org/10.2147/VHRM.S20181

Published 19 July 2011

Jennifer Uzan1, Marie Carbonnel1, Olivier Piconne1,3, Roland Asmar2, Jean-Marc Ayoubi1
1Department of Gynecology and Obstetrics, Hôpital Foch, Suresnes, France; 2Foundation Medical Research Institutes, Geneva, Switzerland; 3Department of Gynecology and Obstetrics, Hôpital Antoine Béclère, Clamart, France

Abstract: The incidence of pre-eclampsia ranges from 3% to 7% for nulliparas and 1% to 3% for multiparas. Pre-eclampsia is a major cause of maternal mortality and morbidity, preterm birth, perinatal death, and intrauterine growth restriction. Unfortunately, the pathophysiology of this multisystem disorder, characterized by abnormal vascular response to placentation, is still unclear. Despite great polymorphism of the disease, the criteria for pre-eclampsia have not changed over the past decade (systolic blood pressure >140 mmHg or diastolic blood pressure ≥90 mmHg and 24-hour proteinuria ≥0.3 g). Clinical features and laboratory abnormalities define and determine the severity of pre-eclampsia. Delivery is the only curative treatment for pre-eclampsia. Multidisciplinary management, involving an obstetrician, anesthetist, and pediatrician, is carried out with consideration of the maternal risks due to continued pregnancy and the fetal risks associated with induced preterm delivery. Screening women at high risk and preventing recurrences are key issues in the management of pre-eclampsia.

Keywords: pre-eclampsia, epidemiology, pathophysiology, therapeutic management

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Short-term outcome of patients with preeclampsia

Koual M, Abbou H, Carbonnel M, Picone O, Ayoubi JM

Vascular Health and Risk Management 2013, 9:143-148

Published Date: 15 April 2013

Readers of this article also read:

Short-term outcome of patients with preeclampsia

Koual M, Abbou H, Carbonnel M, Picone O, Ayoubi JM

Vascular Health and Risk Management 2013, 9:143-148

Published Date: 15 April 2013

The role of genetics in pre-eclampsia and potential pharmacogenomic interventions

Williams PJ, Morgan L

Pharmacogenomics and Personalized Medicine 2012, 5:37-51

Published Date: 20 January 2012

Current state of cardiac rehabilitation in Germany: patient characteristics, risk factor management and control status, by education level

Bestehorn K, Jannowitz C, Horack M, Karmann B, Halle M, Völler H

Vascular Health and Risk Management 2011, 7:639-647

Published Date: 31 October 2011

Superficial venous thrombosis: disease progression and evolving treatment approaches

Litzendorf ME, Satiani B

Vascular Health and Risk Management 2011, 7:569-575

Published Date: 31 August 2011

Extended-release ranolazine: critical evaluation of its use in stable angina

Truffa AAM, Newby LK, Melloni C

Vascular Health and Risk Management 2011, 7:535-539

Published Date: 25 August 2011

Lipid-lowering therapy: who can benefit

Lewis SJ

Vascular Health and Risk Management 2011, 7:525-534

Published Date: 24 August 2011

Diagnosis and management of pre-eclampsia: an update

Judi A Turner

International Journal of Women's Health 2010, 2:327-337

Published Date: 30 September 2010

Current use of contraceptive method among women in a middle-income developing country

Paul A Bourne, Christopher AD Charles, Tazhmoye V Crawford, et al

Open Access Journal of Contraception 2010, 1:39-49

Published Date: 22 June 2010

Efficacy and safety of rosuvastatin in the management of dyslipidemia

Paolo Rubba, Gennaro Marotta, Marco Gentile

Vascular Health and Risk Management 2009, 5:343-352

Published Date: 7 April 2009